CN101586162B - Method of extracting target nucleic acid and performing PCR amplification - Google Patents
Method of extracting target nucleic acid and performing PCR amplification Download PDFInfo
- Publication number
- CN101586162B CN101586162B CN2009100436522A CN200910043652A CN101586162B CN 101586162 B CN101586162 B CN 101586162B CN 2009100436522 A CN2009100436522 A CN 2009100436522A CN 200910043652 A CN200910043652 A CN 200910043652A CN 101586162 B CN101586162 B CN 101586162B
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- target nucleic
- pcr
- performing pcr
- augmentation detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 63
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 43
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 43
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 43
- 238000012408 PCR amplification Methods 0.000 title claims description 17
- 238000001514 detection method Methods 0.000 claims abstract description 32
- 238000006243 chemical reaction Methods 0.000 claims abstract description 27
- 230000003416 augmentation Effects 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000012295 chemical reaction liquid Substances 0.000 claims abstract description 4
- 239000000523 sample Substances 0.000 claims description 35
- 238000000605 extraction Methods 0.000 claims description 19
- 230000003321 amplification Effects 0.000 claims description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 15
- 238000003753 real-time PCR Methods 0.000 claims description 15
- 239000006166 lysate Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 8
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 6
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 6
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 6
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 6
- 238000013016 damping Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 5
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 4
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 238000013461 design Methods 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000005336 cracking Methods 0.000 abstract description 3
- 244000000010 microbial pathogen Species 0.000 abstract description 3
- 238000009582 blood typing Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 238000011002 quantification Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 41
- 241000700721 Hepatitis B virus Species 0.000 description 25
- 239000000243 solution Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 11
- 238000009835 boiling Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 239000004141 Sodium laurylsulphate Substances 0.000 description 7
- 230000005291 magnetic effect Effects 0.000 description 7
- 230000005298 paramagnetic effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000012925 reference material Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000002934 lysing effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- -1 methane amide Chemical class 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000001921 nucleic acid quantification Methods 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method of extracting target nucleic acid and performing PCR augmentation comprises the following steps: adding a cracking liquid, a sample containing target nucleic acid and a reaction liquid which performs PCR augmentation into a PCR reaction tube and evenly mixing; placing in the PCR apparatus for performing PCR augmentation. The invention only needs simple instrument to rapidly and high efficiently extract target nucleic acid from the sample and to synchronously perform real-time fluorescence PCR augmentation detection; the invention has wide detection linear range, accurate quantification for samples of different concentrations, good specificity and good repetitiveness; the invention is extremely simple in operation and suitable for the PCR apparatus of different types; it can be widely applied to the fields of detection of pathogenic microorganism, medicolegal expertise, tissue and blood typing, genetic mutation detection.
Description
Technical field
The present invention relates to a kind of go forward side by side method of performing PCR augmentation detection of target nucleic acid of extracting.
Background technology
Since round pcr in 1985 came out, this technology had been applied to each message area of life science, because of its susceptibility height, high specificity, easy and simple to handle, advantage such as required time is short, had been widely used in the detection of pathogenic micro-organism at present.Owing to contain materials such as protein, lipid in the clinical samples, can disturb the PCR reaction, so before doing the PCR reaction, must carry out nucleic acid extraction.The first step of PCR detection technique is exactly the preparation of template DNA, i.e. the extraction of DNA in the sample, and this directly affects the result of PCR reaction.For a long time, the extraction of DNA and purifying are consuming time, loaded down with trivial details processes always in the sample, and detection speed has seriously slowed down.
At present, the extracting method of DNA comprises two steps in the sample: lysing cell and extraction nucleic acid.Lysing cell, the common method that DNA is discharged comprise physics method (boil, freeze thawing, microwave, ultrasonic, grinding etc.), chemical process (high salt, surfactant SDS, hot phenol etc.) and enzymolysis process (lyase, N,O-Diacetylmuramidase, Proteinase K etc.).
Phenol extraction process, isopropanol precipitating method and methane amide cracking process are to extract DNA classic methods the most, the improvement of at present a lot of methods all is to carry out on the basis of these methods, and these three kinds of methods all are to utilize Proteinase K and sodium lauryl sulphate (SDS) digestion smudge cells.In preceding two kinds of methods, lysate is removed protein with phenol/chloroform earlier, more respectively with ethanol or isopropanol precipitating DNA.The methane amide method is to utilize the methane amide depolymerization protein of high density and combining of DNA, utilizes dialysis to handle the DNA sample then.The DNA purity that these classical ways obtain is very high, can satisfy the requirement of various tests, but complex operation is used duration, and agents useful for same has certain toxicity.
The method for extracting nucleic acid that is applied to the real-time fluorescence quantitative PCR detection at present mainly contains three kinds, i.e. alkaline lysis, boiling lysis and paramagnetic particle method.
Alkaline lysis is under high pH (12.0～12.6) condition that NaOH provides, and destroys cell walls with strong cation washing agent SDS, and lysing cell makes the protein generation sex change of cell jointly with NaOH, discharges DNA.After the cracking, the protein of cell wall fragments and sex change and other impurity form big mixture, and these mixtures can effectively precipitate, and DNA remain in the supernatant liquor under high sylvite condition, again by step purify DNAs such as dehydrated alcohol precipitation, washing with alcohol.Though alkaline lysis is fast and convenient, the Deproteinization effect is not good enough, has obviously influenced the PCR effect.
The boiling lysis principle, be when boiling, the DNA in the sample to be discharged by the effect that contains lysis buffers such as Proteinase K, be dissolved in the damping fluid, in the time of the boiling water bath lysing cell, the base pairing of DNA chain be can destroy, and the protein and the chromosomal DNA sex change of cell made.Remove protein and other impurity of sex change by centrifugation, the DNA that reclaims then in the supernatant liquor is used for pcr amplification.Yet through high-temperature boiling, protein coagulation is wrapped part nucleic acid and loses with centrifugation, directly causes template nucleic acid amount minimizing in the supernatant liquor; In addition, though, still contain composition such as albumen, heparin and the micro-oxyphorase etc. of a small amount of suppression of amplification in the supernatant liquor, suppressed amplification efficiency through boiling and precipitating at a high speed.
Paramagnetic particle method is the method for extracting nucleic acid that just grew up in recent years, it is by the cell pyrolysis liquid lysing cell that paramagnetic particle method extracts nucleic acid, the nucleic acid molecule that dissociates out from cell is by the special magnetic-particle surface that is adsorbed onto, and impurity such as protein are not adsorbed, and stays in the solution.After the reaction certain hour, under the action of a magnetic field, magnetic-particle and liquid are separated again, reclaim particle (being magnetic bead-DNA mixture), use the elutriant wash-out again, obtain purified DNA.Advantages such as because its reagents series do not contain the big organic solvents of toxicity such as chloroform, phenol, extraction step is simpler, and high and purity is good to the rate of recovery of sample of nucleic acid and extremely the investigator favor.But product is essentially external and monopolizes, and price is very expensive, thereby has limited its widespread use in China.
No matter be classical way or various improved method, all must pay close attention to following three main points: the first, the yield of goal gene; The second, the simplified and traditional degree of schedule of operation; Three, the consumption of material and time.Above the whole bag of tricks all must just can carry out PCR and detect after extracting purification of nucleic acid, it is painstaking to compare unavoidably when handling a large amount of clinical sample.
Summary of the invention
The object of the present invention is to provide a kind of used equipment simple, easy and simple to handle, the go forward side by side method of performing PCR augmentation detection of the extraction target nucleic acid that cost is low.
The go forward side by side method of performing PCR amplification of the present invention's extraction nucleic acid comprises the steps: a kind of lysate, a kind of sample and a kind of reaction solution that carries out pcr amplification that contains target nucleic acid are added in the PCR reaction tubes, mixes, and places the enterprising performing PCR amplification of PCR instrument.
Behind lysate, the sample that contains target nucleic acid and the pcr amplification reaction liquid mixing, should leave standstill 3-8 minute, and then place the enterprising performing PCR amplification of PCR instrument.
Described lysate is dissolved in the KCl (mass volume ratio) of 50～200mM by the surfactant peptides of 0.01～0.5mM (mass volume ratio), the SDS of 0.01%～2% (volume), LLS, Chelex-100 (mass volume ratio), and the ethanol of 0.05%～1% (volume) is formed.
The testing sample that contains target nucleic acid can be serum, blood plasma, juice or sputum.
Described nucleic acid can be DNA or RNA.
Pcr amplification reaction liquid (hereinafter to be referred as " PCR reaction solution ") comprises the pcr amplification damping fluid, is selected from the mixture of 4 kinds of dNTP among dATP, dCTP, dGTP, dTTP or the dUTP, archaeal dna polymerase, and magnesium ion is at the upstream and downstream primer of target gene design; According to the various objectives of real-time fluorescence quantitative PCR, also comprise fluorescence dye or according to the custom-designed primer of target sequence and with the probe of target sequence specific hybridization.The proportioning of these materials generally is the reaction system adjustment according to different experiments, as dNTPs, the 1 * PCR buffer of Mg2+, the 0.2-0.4mM of the archaeal dna polymerase of 1-5U, 3-5.5mM; The upstream primer of 50-900nM, the downstream primer of 50-900nM are determined to determine to add amount of substance (referring to aftermentioned embodiment) again after the concentration
The mixture ratio of described 4 kinds of dNTP, the ratio of dATP: dCTP: dGTP: dTTP was generally 1: 1: 1: 1; The ratio of dATP: dCTP: dGTP: dUTP is 1: 1: 1: 2.
Proportioning is unrestricted between described lysate, the testing sample that contains target nucleic acid, these three kinds of materials of PCR reaction solution, promptly can be any ratio, but more preferably proportioning is 1: 1-3: 10-25; The order that is mixed does not have strict restriction yet, but suitable last interpolation of PCR reaction solution.
Except that lysate, the testing sample that contains target nucleic acid, PCR reaction solution, also can add interior mark as required.
Be designated as the section of DNA fragment similar of known low levels in described to template amplification efficient, its is added in PCR reaction solution, increase jointly, can react every pipe situation that increases really with template, if interior mark and sample all do not amplify the result, represent that then this pipe amplification is invalid.
Described pcr amplification comprises simple PCR, linear amplification and real-time fluorescence quantitative PCR.
Advantage of the present invention is: only need simple equipment, as liquid-transfering gun, PCR reaction tubes; Two kinds of simple reagent (lysate, PCR reaction solution) can rapidly and efficiently extract target nucleic acid and carry out the real-time fluorescence quantitative PCR augmentation detection synchronously from sample.
Simultaneously, the inventive method detects linear wide ranges, and for samples of different concentrations, quantitatively accurately, specificity is good, good reproducibility.
Compare with present existing nucleic acid extraction and PCR detection method, the present invention's operation is especially easy, operation near automatization has guaranteed that experimental result is stable, difference and the mistake of avoiding manual operation to cause, be applicable to dissimilar PCR instrument, can be widely used in the detection of pathogenic micro-organism, medical jurisprudence is identified, tissue and blood grouping, fields such as the detection of transgenation.
Description of drawings
Fig. 1 (a) detects the positive reference material of HBV DNA national standard product for the inventive method;
Fig. 1 (b) detects the negative reference material of HBV DNA national standard product for the inventive method;
Fig. 2 detects HBV DNA positive serum for the inventive method, and concentration is respectively 1.0 * 10 from left to right
7IU/ml, 1.0 * 10
6IU/ml, 1.0 * 10
5IU/ml, 1.0 * 10
4IU/ml
Fig. 3 (a) detects HBV DNA positive serum for the inventive method, and concentration is 500IU/ml
Fig. 3 (b) detects HBV DNA positive serum for the inventive method, and concentration is 300IU/ml
Fig. 3 (c) detects HBV DNA positive serum for the inventive method, and concentration is 200IU/ml
Fig. 4 detects HBV DNA and corresponding interior mark for the inventive method.
Embodiment
Below in conjunction with embodiment the present invention is made and to further specify:
The fluorescence quantitative PCR detection embodiment of embodiment 1:HBV DNA
Draw 2 microlitre lysates (surfactant peptides of 0.1mM is dissolved in 80mM KCl, 0.1%SDS, 0.5% ethanol) with band filter core suction nozzle, 3 microlitre samples to be tested (known HBV DNA male serum or blood plasma), add in the PCR reaction tubes, the liquid-transfering gun head is inhaled and is beaten mixing, after leaving standstill 5min, draw the PCR reaction solution that 45ul has prepared with band filter core suction nozzle, on Stratagene Mx3000P or ABI7300 PCR instrument, carry out the real-time fluorescence quantitative PCR amplification.
Each constituent concentration of PCR reaction solution and ratio are as follows:
| Composition | Single part of consumption |
| (upstream) primer HBV-F1 (50pmol/ μ l) | 0.2μl |
| (downstream) primer HBV-F1 (50pmol/ μ l) | 0.2μl |
| HBV probe HBV-P1 (50pmol/ μ l) | 0.1ul |
| ROX solution (10 μ mol/L) | 1ul |
| dNTPs | 0.4 |
| 10×PCR?buffer | 5μl |
| The sterilization purified water | 38.1μl |
| Total amount | 45μl |
The PCR response procedures is:
1) with the yin and yang attribute reference material in the HBV national standard product as sample to be checked, adopt the inventive method on the StratageneMx3000P instrument, to detect, detect the yin and yang attribute coincidence rate.Be 9 positive reference materials in the national standard product as Fig. 1 (a), utilization the present invention detects positive entirely, and Fig. 1 (b) is 8 negative reference materials, and is negative entirely after testing.Utilization the inventive method is carried out HBV DNA fluorescence quantitative PCR detection and is had good specificity.
2) the HBV DNA positive serum of 4 kinds of concentration of demarcating with Chinese biological goods calibratings institute (middle inspection institute) hepatitis B virus (HBV) nucleic acid quantification standard substance is a sample to be tested, and concentration is respectively 1.0 * 10
7IU/ml, 1.0 * 10
6IU/ml, 1.0 * 10
5IU/ml, 1.0 * 10
4IU/ml, each concentration repeated experiments 3 times, the result is as shown in Figure 2, the variation coefficient of CT value is respectively: 0.25%, 0.44%, 0.48%, 0.36%, the variation coefficient all in 1%, this shows that utilization the inventive method detects the repeated fine of serum sample.
3) the HBV positive serum of demarcating with middle inspection institute hepatitis B virus (HBV) nucleic acid quantification standard substance is initial sample, be diluted to 500IU/ml, 300IU/ml, 200IU/ml, each concentration repeats 5 times, as Fig. 3,500IU/ml, the amplification of the sample standard deviation 100% of 300IU/ml, and only 1 the sample of 200IU/ml does not have amplification, can reach 300IU/ml so utilization the inventive method is carried out fluorescence quantitative PCR detection sensitivity.
4) be sample to be tested with the linear sensitivity reference material in the HBV national standard product, (concentration is respectively 1.0 * 10 with the positive criteria product of gradient dilution
7IU/ml, 1.0 * 10
6IU/ml, 1.0 * 10
5IU/ml, 1.0 * 10
4IU/ml) adopt fast method of the present invention to detect the accordance of analyzing and testing value and theoretical value:
| Linear sensitivity reference material | Quality standard (IU/ml) | The theoretical concentration logarithmic value | Detected value | The detectable level logarithmic value |
| L0 | 7.762×10 7～6.165×10 8 | 8.342 | 2.55×10 8 | 8.407 |
| L1 | 1.479×10 7～1.175×10 8 | 7.619 | 3.54×10 7 | 7.549 |
| L2 | 1.585×10 6～1.259×10 7 | 6.649 | 4.43×10 6 | 6.646 |
| L3 | 1.659×10 5～1.318×10 6 | 5.672 | 3.41×10 5 | 5.382 |
| L4 | 1.820×10 4～1.479×10 5 | 4.715 | 1.38×10 4 | 4.140 |
| L5 | 1.514×10 3～1.230×10 4 | 3.636 | 1.71×10 3 | 3.233 |
| L6 | 3.890×10 1～3.090×10 2 | 2.043 | 5.64×10 1 | 1.751 |
The double logarithmic curve linearly dependent coefficient (r) of theoretical concentration and detectable level is 0.9993, and it is quantitatively very accurate that utilization this method is carried out the real-time fluorescence quantitative PCR detection.
Embodiment 2:HBV DNA and corresponding interior target rapid fluorescence quantitative PCR detection embodiment
Method as embodiment 1, draw 2 microlitre lysates (surfactant peptides of 0.1mM is dissolved in 80mM KCl, 0.1%SDS, 0.5% ethanol) with band filter core suction nozzle, 3 microlitre samples to be tested (known HBV DNA male serum or blood plasma), add in the PCR reaction tubes, the liquid-transfering gun head is inhaled and is beaten mixing, leaves standstill about 5min.Add mark (10 in the 0.3ul according to stoichiometric number according to every reaction
4Copies/ul) ratio adds interior mark in the PCR reaction solution.Present embodiment has selected for use lower concentration HBV dna sample (concentration is 500IU/ml, 200IU/ml) and a negative sample as sample to be tested.As Fig. 4, higher one group of fluorescent signal is interior target amplification curve, and one group that fluorescent signal is lower is the amplification curve of sample to be tested, and interior mark amplification is normal and detect sample for lower concentration and do not have influence.In be designated as the section of DNA fragment similar of known low levels to template amplification efficient, it is added in the PCR reaction solution, increase jointly with template, can react every pipe situation that increases really, if interior mark and sample all do not amplify the result, represent that then this pipe amplification is invalid, mark monitoring in this fast method can add and have good effect.
Experiment showed, that by hepatitis B virus thymus nucleic acid (HBV DNA) utilization Taqman real-time fluorescence quantitative PCR is carried out absolute quantitation the inventive method detects linear wide ranges, for samples of different concentrations, quantitatively accurately, specificity is good, good reproducibility.
Reference examples 1: boiling method extracts HBV DNA and fluorescence quantitative PCR detection
Boiling method the inventive method
At present domestic have a lot of employing boiling methods extraction nucleic acid and carry out the HBV detection by quantitative, but sensitivity only can reach 500IU/ml or 10
3More than the IU/ml, and the inventive method sensitivity is than the boiling method height, and operation is easier.
Reference examples 2: paramagnetic particle method extracts HBV DNA and fluorescence quantitative PCR detection
Paramagnetic particle method: add cell pyrolysis liquid in the sample to be tested, after treating lysis, in lysate, add magnetic bead, when the pH value of solution less than 6.5 the time, magnetic bead optionally combines with the DNA that optimizes, the magnetic bead that will be adsorbed with DNA this moment places magnetic field, remove the impurity (albumen etc.) that is not adsorbed by damping fluid, then magnetic bead is placed the damping fluid of pH value 8.5, the DNA of purifying can enter damping fluid, and the machine of going up in the DNA adding PCR reaction solution with wash-out carries out real-time fluorescence quantitative PCR and detects.
In the present known data, it is low slightly than paramagnetic particle method that the sensitivity of utilization paramagnetic particle method extraction nucleic acid and amplification can reach the sensitivity of 10IU/ml the inventive method, but easy relatively a lot of in operation.
Claims (9)
1. one kind is extracted the go forward side by side method of performing PCR augmentation detection of target nucleic acid, it is characterized in that, comprises the steps: lysate, the reaction solution that contains the sample of target nucleic acid and carry out pcr amplification are added in the PCR reaction tubes, mixes, and places the enterprising performing PCR amplification of PCR instrument;
Described lysate is dissolved in the KCl (mass volume ratio) of 50～200mM by the surfactant peptides of 0.01～0.5mM (mass volume ratio), the SDS of 0.01%～2% (volume), LLS, Chelex-100 (mass volume ratio), and the ethanol of 0.05%～1% (volume) is formed.
2. the go forward side by side method of performing PCR augmentation detection of extraction target nucleic acid according to claim 1 is characterized in that, behind lysate, the sample that contains target nucleic acid and pcr amplification reaction liquid mixing, leaves standstill 3-8 minute earlier, and then places the enterprising performing PCR amplification of PCR instrument.
3. the go forward side by side method of performing PCR augmentation detection of extraction target nucleic acid according to claim 1 and 2 is characterized in that described nucleic acid is DNA or RNA.
4. the go forward side by side method of performing PCR augmentation detection of extraction target nucleic acid according to claim 1 and 2, it is characterized in that, the reaction solution that carries out pcr amplification comprises the pcr amplification damping fluid, be selected from the mixture of 4 kinds of dNTP among dATP, dCTP, dGTP, dTTP and the dUTP, archaeal dna polymerase, magnesium ion is at the upstream and downstream primer of target gene design.
5. the go forward side by side method of performing PCR augmentation detection of extraction target nucleic acid according to claim 4 is characterized in that the mixture ratio of described 4 kinds of dNTP, the ratio of dATP: dCTP: dGTP: dTTP are 1: 1: 1: 1; The ratio of dATP: dCTP: dGTP: dUTP is 1: 1: 1: 2.
6. the go forward side by side method of performing PCR augmentation detection of extraction target nucleic acid according to claim 4 is characterized in that, also comprise fluorescence dye or according to the custom-designed primer of target sequence and with the probe of target sequence specific hybridization.
7. the go forward side by side method of performing PCR augmentation detection of extraction target nucleic acid according to claim 1 and 2 is characterized in that the testing sample that contains target nucleic acid is serum, blood plasma, juice or sputum.
8. the go forward side by side method of performing PCR augmentation detection of extraction target nucleic acid according to claim 1 and 2 is characterized in that pcr amplification is simple PCR, linear amplification or real-time fluorescence quantitative PCR.
9. the go forward side by side method of performing PCR augmentation detection of extraction target nucleic acid according to claim 4 is characterized in that the proportioning between lysate, the testing sample that contains target nucleic acid, the PCR reaction solution is 1: 1-3: 10-25.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100436522A CN101586162B (en) | 2009-06-10 | 2009-06-10 | Method of extracting target nucleic acid and performing PCR amplification |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100436522A CN101586162B (en) | 2009-06-10 | 2009-06-10 | Method of extracting target nucleic acid and performing PCR amplification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101586162A CN101586162A (en) | 2009-11-25 |
| CN101586162B true CN101586162B (en) | 2011-02-09 |
Family
ID=41370588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100436522A Active CN101586162B (en) | 2009-06-10 | 2009-06-10 | Method of extracting target nucleic acid and performing PCR amplification |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101586162B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101701267B (en) * | 2009-11-26 | 2012-09-19 | 戴立忠 | Fluorescence quantitative PCR detection kit of hepatitis B virus and application thereof |
| KR20160088958A (en) * | 2010-02-23 | 2016-07-26 | 루미넥스 코포레이션 | Apparatus and methods for integrated sample preparation, reaction and detection |
| CN102807975B (en) * | 2011-05-30 | 2014-10-29 | 熊慧 | Method for rapidly extracting nucleic acid from biological sample |
| CN103184214B (en) * | 2011-12-27 | 2016-02-10 | 上海星耀医学科技发展有限公司 | A kind of hbv nucleic acid rapid extraction reagent |
| CN104450674A (en) * | 2013-09-24 | 2015-03-25 | 上海艾迪康医学检验所有限公司 | Nucleic acid extraction and preservation solution |
| CN114921524A (en) * | 2017-04-28 | 2022-08-19 | 利多(香港)有限公司 | Method for detecting and neutralizing sample nucleic acid |
| CN108531563A (en) * | 2018-02-05 | 2018-09-14 | 深圳市尚维高科有限公司 | The purposes and lysate of porous microsphere and the application method of lysate |
| CN108977436A (en) * | 2018-08-10 | 2018-12-11 | 邵忠民 | Biotinylated nucleic acid DNA quick release extracts reagent and preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1712547A (en) * | 2005-02-01 | 2005-12-28 | 合肥中科大生物技术有限公司 | Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA |
| CN1873023A (en) * | 2006-04-14 | 2006-12-06 | 武汉大学 | Fluorescence quantitative kit PCR for quick testing chlamydia trachomatis |
-
2009
- 2009-06-10 CN CN2009100436522A patent/CN101586162B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1712547A (en) * | 2005-02-01 | 2005-12-28 | 合肥中科大生物技术有限公司 | Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA |
| CN1873023A (en) * | 2006-04-14 | 2006-12-06 | 武汉大学 | Fluorescence quantitative kit PCR for quick testing chlamydia trachomatis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101586162A (en) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101586162B (en) | Method of extracting target nucleic acid and performing PCR amplification | |
| EP3636769B1 (en) | Sample nucleic acid measurement test kit, reagent, and application thereof | |
| CN107299097A (en) | A kind of micro-nucleic acid releasing agent, preparation method and applications | |
| CN105018485A (en) | Primer and probe for detecting peste des petits ruminants virus by virtue of RPA (Recombinase Polymerase Amplification) technique | |
| CN111424119B (en) | High-flux detection primer and kit for SARS-CoV-2 virus | |
| CN101144771B (en) | Reagent kit for detecting human HIV | |
| CN111304361A (en) | Kit for detecting African swine fever virus and method for detecting African swine fever virus | |
| CN112195278A (en) | Six respiratory tract virus nucleic acid detection kit and use method thereof | |
| CN108070636A (en) | A kind of processing method and kit of fluorescent PCR amplified sample | |
| CN102827947B (en) | Kit and detection method for rapid quantitative detection of hepatitis virus nucleic acid | |
| CN103184214A (en) | Hepatitis B virus nucleic acid rapid extraction reagent | |
| CN106497916A (en) | A kind of construction method in the NK cell polygenic variations library for high-flux sequence detection and its application | |
| CN113718064A (en) | Probe primer combination, kit and application for identifying PCV2 and PCV3 | |
| CN106987588B (en) | Virus/bacteria lysate and fluorescent quantitative PCR detection method | |
| CN103540687A (en) | LAMP detection primer group and kit for white spot syndrome virus (WSSV) | |
| CN115323075B (en) | RT-RAA primer probe group and kit for detecting infectious bronchitis viruses and genotyping and application of RT-RAA primer probe group and kit | |
| CN113930418A (en) | Nucleic acid releasing agent and method for releasing nucleic acid | |
| CN107365766A (en) | Mechanical crushing method extraction mycotic spore RNA method | |
| CN110684862B (en) | Microdroplet digital PCR kit for quantitatively detecting hepatitis B virus and detection method | |
| CN113151579A (en) | Primer and detection method for dual real-time fluorescent quantitative PCR (polymerase chain reaction) detection of duck hepatitis A virus 1 and duck astrovirus 3 | |
| CN111154836A (en) | Targeted nucleic acid capture and detection methods | |
| CN114990261B (en) | Multiplex qPCR detection reagent for detecting respiratory tract infectious disease pathogens | |
| CN117568493B (en) | Reagent and kit for identifying insect cell line | |
| AU2021103963A4 (en) | Paper-based chromatographic viral nucleic acid extraction kit | |
| CN117403009B (en) | Reagent and kit for combined detection of four bovine-derived RNA viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20091125 Assignee: Sansure Biotech Inc. Assignor: Dai Lizhong Contract record no.: 2013430000093 Denomination of invention: Method of extracting target nucleic acid and performing PCR augmentation Granted publication date: 20110209 License type: Exclusive License Record date: 20130626 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGWEI GENE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: DAI LIZHONG Effective date: 20141203 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410205 CHANGSHA, HUNAN PROVINCE TO: 410012 CHANGSHA, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141203 Address after: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Patentee after: HUNAN SHENGWEI GENE TECHNOLOGY CO., LTD. Address before: 410205 No. 198 west slope, Yuelu District, Hunan, Changsha, Tongzi Patentee before: Dai Lizhong |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160706 Address after: 410012 No. 680, Lu Song Road, Changsha hi tech Industrial Development Zone, Hunan Patentee after: Sansure Biotech Inc. Address before: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Patentee before: HUNAN SHENGWEI GENE TECHNOLOGY CO., LTD. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method of extracting target nucleic acid and performing PCR augmentation Effective date of registration: 20170711 Granted publication date: 20110209 Pledgee: Ningbo free trade zone Terry with equity investment partnership (limited partnership)|Suzhou equity equity investment center (limited partnership)|Ningbo Meishan Bonded Port District, Jun and equity investment partnership (limited partnership)|Chen Bang Pledgor: Hunan Gene Technology Co.|Hunan San Xiang Biological Technology Co. Ltd. Registration number: 2017430000042 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| CP03 | Change of name, title or address |
Address after: 410205 Changsha province high and New Technology Industrial Development Zone, Lu Pine Road, No. 680, Hunan Patentee after: Shengxiang Biotechnology Co., Ltd Address before: 410012 No. 680, Lu Song Road, Changsha hi tech Industrial Development Zone, Hunan Patentee before: Sansure Biotech Inc. |
|
| CP03 | Change of name, title or address | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200217 Granted publication date: 20110209 Pledgee: Suzhou Lirui equity investment center (limited partnership)|Triton equity investment partnership (limited partnership)|JUNHE Tongrui equity investment partnership (limited partnership)|Chenbang Pledgor: SANSURE BIOTECH Inc. Registration number: 2017430000042 |